The firm believes that clinical data generated to date from two patients may be sufficient to support accelerated approval of PM359.
検索と置換が使える遺伝子エディター。 人気の遺伝子編集ツールCRISPRですが、難なしというわけにはまいりません。新しく開発された遺伝子編集技術では、CRISPR最大の欠点いくつかを克服したようです。 遺伝子編集技術の理想は、まるでシンプルにパーツ ...
Prime Medicine, Inc. ( (PRME)) has issued an announcement. On January 12, 2026, Prime Medicine, Inc. released an updated corporate presentation outlining its progress and near-term plans for its Prime ...
CAMBRIDGE, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic ...
In a new study published in Nature, researchers from the Massachusetts Institute of Technology (MIT) showcased engineered prime editors with significantly lower rates of indel formation. “This paper ...
一部の結果でアクセス不可の可能性があるため、非表示になっています。
アクセス不可の結果を表示する